Talus Bio

"Open-source scientific software is not just a good idea; it’s a philosophy that embodies transparency, collaboration, and progress." This quote from the excellent article by our Head of Data Science and Engineering, William Fondrie, perfectly describes values that Talus Bio vigorous promotes and hopes to embody. Nice work, Will! https://lnkd.in/gKPpdF2x

Congratulations to Talus Bio co-founder and CTO, Lindsay Pino! The Human Proteome Organization honored Lindsay with the 2024 HUPO Rising Star Award. The award recognizes her contributions to the field of proteomics, from her research excellence and entrepreneurial spirit, to her educational and community-building efforts that have helped propel the field to the next wave of discovery. At Talus Bio, Lindsay is the driving force behind our MARMOT platform that leverages functional proteomics, automated biology, and machine learning to discover first-in-class treatments for cancer and diseases caused by transcription factor dysregulation. Join us in celebrating her accomplishments and this well-deserved recognition!

Thanks to Talus Bio board member, Omri Amirav-Drory from NFX, for this insightful blog post that clearly articulates the rationale behind the parallel business models of developing a platform and developing assets, because "great platforms should make great assets". We couldn't agree more!

We're proud of Lindsay Pino's willingness to volunteer her time and expertise within the Skyline community! This is a great example of one of the many ways that Talus Bio's leadership team is giving back to fellow proteomics scientists.

Congratulations to our new Head of Biology, Gaelle Mercenne, for being featured in STAT's’ “Up & Down the Ladder.” We learned so much about her, for example, if she were a piece of lab equipment she’d be a plate shaker: "I want to know what is possible and what is not possible when considering drug targets, especially transcription factors. What is druggable? I love using new techniques to identify small molecules that inhibit previously considered undruggable targets. So the idea of being something to shake things up and challenging concepts and questions, it’s who I am.” At Talus Bio, we’ve got a lot of movers n’ shakers on the team–but only one Gaelle. Read the whole conversation with our newest team member in ed silverman's latest column, linked in comments (subscription required).

Enjoying a Friday evening with Ti Zhao, Ivan Liachko 🇺🇦, Lindsay Pino, and Matthew Bick at the Pack Ventures annual meeting learning about how AI is transforming drug discovery and genomics. We've all been enjoying the recent GenAI wave which is, in part, possible by the huge amount of information that is readily available on the internet to train models. Intetestingly, As Lindsay noted, there are tons of data out there to support drug discovery, but it is not necessarily easy to access and even further, most of the data is about what DOESN'T work so you have to work hard to tell the models what success looks like. We are just starting to scratch the surface at harnessing AI to treat deadly diseases. Pack is a pre-seed and seed-focused venture fund, uniquely positioned within the University of Washington network to support UW spinouts and companies founded by UW alumni. A big part of what I love about being an L.P. in Pack is getting to support some of the smartest founders on the planet and learn about how they are literally taking the fiction out of science fiction. And you can too! Ken Horenstein and Ti are actively raising Fund II and are committed to building a diverse pool of accredited investors, not just those that fall into the ultra high net worth category. If you'd like to explore joining the Pack, let me know and I'd be happy to connect you to learn more.. #venturecapital #startups #innovation #Entrepreneurship #ai #artificialintelligence

We’re proud to welcome Gaelle Mercenne, PhD to the Talus Bio team as our new Head of Biology. A true pioneer at the forefront of AI-accelerated drug discovery, Gaelle will leverage our MARMOT platform to identify novel targets and optimize transcription factor modulators. “Bringing Gaelle aboard allows us to accelerate new molecules from hits identified by the MARMOT platform to fully optimized, first-in-class drugs to address diseases driven by transcription factor dysregulation.” – Talus Bio co-founder & CEO, Alex Federation, PhD Gaelle brings the deep expertise necessary to expand our pipeline of transcription factor therapeutics for cancer, inflammatory, cardiometabolic, and rare diseases. Prior to joining the team, she was a pivotal early hire at Recursion Pharmaceuticals before serving as Associate Director of Research Innovation at Sumitomo Pharma America. Follow the links in this post's comments section to learn more about Gaelle and Talus Bio’s mission to accelerate drug development for the most challenging therapeutic targets.

Take an inside look at Talus Bio with our COO/CFO Michelle Briscoe, “This company is based on the people and the scientists. They are the ones that—every day—are coming in with these new creative ideas of how to achieve these goals, this mission: which is getting new drugs to patients that previously didn’t have therapeutic options.” Tune in to the Life Science Success Podcast for the full conversation with Don Davis PhD, MBA and hear how the Talus Bio team stays thriving and empowered to achieve their mission-critical work. 🔊 https://lnkd.in/dpTN6BDf

Talus Bio has hired two amazing scientists who were previously venture analysts in this WRF program, Daniele Canzani, PhD and Lillian Tatka, PhD. This unique experience offered them invaluable insights into the business landscape of startups and biotech companies, further strengthening our team. 

With $11.2M in new funding led by Two Bear Capital, Talus Bio is set to revolutionize the way we approach drug discovery. Our MARMOT platform is using proteomics and AI to lead the charge against previously "undruggable" transcription factors. Thanks to Gabrielle Masson for highlighting our work https://lnkd.in/gDnp48pW